Toll-like receptor-7 activation in CD8+ T cells modulates inflammatory mediators in patients with rheumatoid arthritis

Rheumatol Int. 2022 Jul;42(7):1235-1245. doi: 10.1007/s00296-021-05050-8. Epub 2022 Feb 10.

Abstract

Rheumatoid arthritis (RA) is an autoimmune disorder of unknown etiology with aberrant immunological responses leading to inflammation, swelling and pain of the joints. CD8+ T cells have been known to be one of the major immune modulators in the progression of RA and the presence of toll-like receptors (TLRs) on these cells further accentuate their role in RA. Herein, we report an increased expression of TLR7 in the endosomes of CD8+ T cells of RA patients correlating with disease severity. The stimulation of TLR7 with Imiquimod (IMQ) in these CD8+ T cells drives the signalling cascade via NFkB and pERK activation and hence an increase in the mRNA transcripts of signature cytokines and cytolytic enzymes. However, a parallel synthesis of Tristetraprolin (TTP), an mRNA destabilizing protein prevents the translation of the mRNA transcripts, leading to a rapid degeneration of the target mRNA. We thus report that a direct TLR7 ligation by its agonist increases cytokine transcript signature but not an equivalent protein surge.

Keywords: CD8+ T cells; IMQ; Rheumatoid arthritis; TLR7; Tristetraprolin.

MeSH terms

  • Arthritis, Rheumatoid*
  • CD8-Positive T-Lymphocytes / metabolism
  • Cytokines / metabolism
  • Humans
  • Inflammation Mediators
  • RNA, Messenger
  • Toll-Like Receptor 7* / genetics
  • Toll-Like Receptor 7* / metabolism
  • Toll-Like Receptors

Substances

  • Cytokines
  • Inflammation Mediators
  • RNA, Messenger
  • TLR7 protein, human
  • Toll-Like Receptor 7
  • Toll-Like Receptors